Health system transitions and engagement for patients with opioid use disorder

Abstract: Background: Opioid Use Disorder (OUD) imposes a rising mortality and health system burden, with opioid related deaths increasing from 8,400 in 2000 to 110,037 in 2023. Medications for opioid use disorder (MOUD) reduce mortality and morbidity, yet only 25.1% of people with OUD are treated with these medications, and inpatient MOUD initiation is inconsistent. Inpatient and Emergency Department (ED) treatment initiation and connection to outpatient care is suboptimal, missing critical opportunities to engage at-risk populations during acute care visits. Our goals were to determine the proportion of patients with OUD treated with MOUD during a hospital/ED stay, and the proportion successfully connected to outpatient care. Methods: This retrospective cohort study included patients 18 years or older with an OUD diagnosis at Duke University Hospital and Duke Regional Hospital (7/1/2023 to 12/31/2025) who had an inpatient or ED encounter with an associated OUD diagnosis code. Primary outcomes were buprenorphine at discharge, 30-day acute care return, and 30 day outpatient follow up. Adjusted modified Poisson regression models with cluster robust standard errors evaluated associations with age, sex, race/ethnicity, insurance, area deprivation index, encounter type, and comorbidity score. Results: Of 5,390 patients with OUD, 42.1% (2,267) had an acute care encounter, generating 3,893 encounters. Neither buprenorphine nor methadone was prescribed at discharge for 46.0% of encounters. Acute care return occurred in 33.6% and outpatient follow up in 32.2% of encounters within 30 days; only 7.4% of follow-ups included a buprenorphine prescription. ED encounters had lower discharge prescribing than inpatient encounters (RR 0.72, 95% CI 0.61,0.86). Black patients had higher 30 day acute care return than White patients (RR 1.16, 95% CI 1.02,1.30) Conclusions: Acute care encounters represent repeated, missed opportunities for MOUD initiation. Disparities were concentrated in post-discharge return and follow up rather than at initial prescribing, and attrition occurred at each transition along the screening-treatment-referral pathway.